Navigation Links
Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
Date:2/20/2008

Conference Call and Webcast to Follow

THE WOODLANDS, Texas, Feb. 20 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its fourth quarter and year end 2007 financial results on Thursday, March 6, 2008 after the financial markets close. Lexicon management will hold a conference call to discuss its clinical development progress, financial results for 2007 and financial guidance for 2008 at 5:00 p.m. Eastern Time on March 6, 2008.

The dial-in number for the conference call is 877-681-3378 (within the United States) or 719-325-4842 (international). The pass code for all callers is 7721341. Investors can access a live webcast of the call at http://www.lexpharma.com. An archived version of the webcast will be available on the website through March 11, 2008.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of cardiology, gastroenterology, immunology and oncology, metabolism, neurology and ophthalmology. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Co., Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
2. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
4. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
5. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
6. Lexicon Pharmaceuticals to Present at Bio InvestorForum
7. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
8. Lexicon Appoints Judith Swain, M.D. to Board of Directors
9. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... Provia ... are necessary in the preparation and development of human cells and tissues for ... the US Food and Drug Administration’s (FDA) Current Good Manufacturing Practices (cGMP) guidelines ...
(Date:7/26/2017)... REHOVOT, Israel (PRWEB) , ... July 26, 2017 ... ... EVGN), a leading company for the improvement of crop productivity and economics for ... a multiyear collaboration. The scope of the agreement includes the research and development ...
(Date:7/25/2017)... CT (PRWEB) , ... July 25, 2017 , ... ... products that enhance the microbiome and improve efficiency of livestock farming while reducing ... that it has licensed additional intellectual property from Cornell University. , These ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):